Copyright: ©Author(s) 2026.
World J Gastroenterol. May 21, 2026; 32(19): 116513
Published online May 21, 2026. doi: 10.3748/wjg.v32.i19.116513
Published online May 21, 2026. doi: 10.3748/wjg.v32.i19.116513
Table 1 Demographics and baseline characteristics for the included analysis sets (n = 1711), n (%)
| Characteristic | n = 1711 |
| Median age (IQR), years | 54.0 (46.0-62.0) |
| Sex | |
| Male | 781 (45.7) |
| Female | 930 (54.4) |
| Comorbidities | |
| Hypertension | 254 (14.9) |
| Diabetes | 142 (8.3) |
| Hyperlipidemia | 29 (1.7) |
| Coronary heart disease | 12 (0.7) |
| Smoking | |
| Yes | 411 (24.0) |
| No | 1300 (76.0) |
| Drinking | |
| Yes | 257 (15.0) |
| No | 1454 (85.0) |
| Preoperative liver biochemistry, median (IQR) | |
| Alanine aminotransferase, U/L | 23.0 (16.0-33.0) |
| Aspartate aminotransferase, U/L1 | 22.0 (17.0-29.0) |
| Total bilirubin, mg/dL2 | 12.0 (9.1-15.7) |
| Alkaline phosphatase, U/L3 | 76.0 (61.0-96.0) |
| Extent of resection | |
| Major resection | 942 (55.1) |
| Minor resection | 769 (44.9) |
- Citation: Xie ZQ, Wei JX, Zhong JY, Luo X, Zhuang HK, Ma XW, Wang QB, Tan WL, Wang BK, Chen YJ, Li CJ, Shang CZ. Effectiveness of magnesium isoglycyrrhizinate on perioperative hepatic function protection in patients undergoing hepatectomy. World J Gastroenterol 2026; 32(19): 116513
- URL: https://www.wjgnet.com/1007-9327/full/v32/i19/116513.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i19.116513